English (UK)
中文版Petrone Group Asia Pacific Pte Ltd 
We are a specialized company in high quality furniture of Investigational Medicinal Product (IMP) and in services for international clinics experimentations , our service has high flexibility in managing clinical trials from phase I to phase IV according to customers’ specific requirements.
Mr. Norberto Pandolfi Orecchia
Managing DirectorPfizer 
Dr. Feng Bian
Sr Director/Emerging Science Lead-China林 王
医学经理Ms. ying wu
ManagerDr. Ying Niu
China Search and Evaluation LeadPhoenix wealth 
Mr. Sai Kunnath
CeoPleiogenix
Dr. Joseph Evans
CEO & PresidentPrivity FZ LLE 
Privity was founded in 2004, an independent Venture-focused advisory firm that seeks entrepreneurs with interesting and unique ideas and helps them develop and grow. Privity is agnostic to geography and industry vertical. It focuses on the quality of the entrepreneur and the compelling value proposition of the idea.
Mr. Sleem Hasan
Founder & CEORancho Santa Fe Bio,Inc.
We licensed the drug from the Mayo Clinic and the drug has been part of the NIH's NCAT's Program in which they put in $5 million for our Phase I and Phase II clinical trials and Sanofi put in another $1 million for manufacturing.
We are raising a Series A round now and we welcome interest from Chinese investors and partners.
You can reach me at 858-205-5091.
Thanks.
----Randy Berholtz
Mr. Randy Berholtz
Chairman and CEO
Regulaxis 
Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.
Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.
Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.
Dr. Matthieu CHAREYRE
Chief Business Development Officer - Global Pharmaceutical Operations
Regulaxis SAS
Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.
Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.
Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.
Responsive Web Design powered by 